Effects of phenotypes in heterocyclic aromatic amine (HCA) metabolism-related genes on the association of HCA intake with the risk of colorectal adenomas by Barbir, Aline et al.
ORIGINAL PAPER
Effects of phenotypes in heterocyclic aromatic amine (HCA)
metabolism–related genes on the association of HCA intake
with the risk of colorectal adenomas
Aline Barbir • Jakob Linseisen • Silke Hermann •
Rudolf Kaaks • Birgit Teucher • Monika Eichholzer •
Sabine Rohrmann
Received: 21 February 2012 / Accepted: 13 June 2012 / Published online: 28 June 2012
 Springer Science+Business Media B.V. 2012
Abstract
Background Heterocyclic aromatic amines (HCA),
formed by high-temperature cooking of meat, are well-
known risk factors for colorectal cancer (CRC). Enzymes
metabolizing HCAs may influence the risk of CRC
depending on the enzyme activity level. We aimed to
assess effect modification by polymorphisms in the HCA-
metabolizing genes on the association of HCA intake with
colorectal adenoma (CRA) risk, which are precursors of
CRC.
Methods A case–control study nested in the EPIC-Hei-
delberg cohort was conducted. Between 1994 and 2005,
413 adenoma cases were identified and 796 controls were
matched to cases. Genotypes were determined and used to
predict phenotypes (i.e., enzyme activities). Odds ratios
(OR) and corresponding 95 % confidence intervals (CI)
were calculated by logistic regression analysis.
Results CRA risk was positively associated with PhIP,
MeIQx, and DiMeIQx (p trend = 0.006, 0.022, and 0.045,
respectively) intake. SULT1A1 phenotypes modified the
effect of MeIQx on CRA risk (pInteraction [ 0.01) such that
the association of MeIQx intake with CRA was stronger for
slow than for normal phenotypes. Other modifying effects
by phenotypes did not reach statistical significance.
Conclusions HCA intake is positively associated with
CRA risk, regardless of phenotypes involved in the metab-
olizing process. Due to the number of comparisons made in
the analysis, the modifying effect of SULT1A1 on the
association of HCA intake with CRA risk may be due to
chance.
Keywords Colorectal adenoma  Genetic polymorphisms 
Phenotypes  Heterocyclic aromatic amines
Introduction
Colorectal cancer (CRC) is the third most common cancer
in the world; in Europe, it ranges on the second place [1].
Studies have shown an increased CRC risk with high intake
of red or processed meat or meat cooked at high temper-
ature [2–4]. Heterocyclic aromatic amines (HCA) are
formed during meat preparation at high temperature
([130 C) due to a chemical reaction from amino acids,
creatinine or creatine, and sugar [5]. The amount of HCA
depends on meat type, cooking time, and meat prepara-
tion like grilling, frying, or barbecuing. PhIP (2-amino-1-
methyl-6-phenylimidazo[4,5-b]pyridine), MeIQx (2-amino-
3,8-dimethylimidazo[4,5-f]quinoxaline), and DiMeIQx (2-
amino-3,4,8-dimethylimidazo[4,5-f]quinoxaline) are the
most common HCAs found in nutrition [6, 7].
A systematic review reported that most epidemiological
studies observed a positive association of HCA intake with
CRC [8]. The carcinogenicity of HCAs is also well known
from animal studies [9, 10]. In contrast, results concerning
colorectal adenomas (CRA), which are well-established
precursors of CRC [8, 11], are inconsistent; up to date a
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dozen studies examined the association of particular HCAs
(PhIP, MeIQx, and DiMeIQx) with the risk of CRA [12–
23]. In our previous study [21], for example, PhIP intake
was associated with an increased relative risk of 1.47
(95 % CI: 1.13–1.93, 4th vs. 1st quartile) with colorectal
adenoma, whereas no associations were observed for
MeIQx and DiMeIQx. The conflicting results may in part
be explained by genetic variation in the metabolism of
HCAs.
Heterocyclic aromatic amines have to be metabolized by
enzymes to become carcinogenic. They need bioactivation
from phase I and phase II enzymes [24]. Firstly, HCAs are
transported to the liver and hydroxylated into N-hydrox-
ylamine by cytochrome P450 1A2 (CYP1A2) [25, 26]. The
resulting N-hydroxyl ion is transported to the colon
mucosa, where it is O-acetylated by N-acetyltransferase 1
(NAT1) and N-acetyltransferase 2 (NAT2) or sulfotrans-
ferase (SULT). N-Acetoxyamin is formed and transported
to the target organ, where reactive nitrenium ions are
formed, which can react with DNA and ultimately result in
CRA. Other enzymes help detoxifying HCAs, such as
glutathione S-transferases (GST) or UDP-glucuronyl-
transferases (UGT) [4, 26]. We have previously observed
some effects of genetic polymorphisms on CRA risk [27].
According to the HCA-metabolizing process, interactions
of fast activating and slow detoxifying HCA-metabolizing
phenotypes may increase the risk of CRA in association
with HCA intake. Vice versa, the combination of slow
activating and fast detoxifying HCA-metabolizing pheno-
types may decrease the association of HCA intake with the
CRA risk.
There are only a limited number of studies looking at
genetic polymorphisms with respect to the association of
HCA intake with the CRA risk [13, 14, 19, 23, 28]. Most of
these studies considered only a few of the relevant
polymorphisms.
In this study, we evaluated the modifying effect of
genetic polymorphisms from 7 enzymes involved in the
HCA metabolism (CYP1A2, NAT1, NAT2, SULT1A1,
GSTA1, UGT1A7, and UGT1A9) on the association of
HCA with CRA risk, setting the focus on phenotypes that
were predicted from genotypes.
Methods
Study design and population
The European Prospective Investigation into Cancer and
Nutrition (EPIC) is a large European-wide prospective
cohort study investigating the etiology of cancers with
detailed information on lifestyle factors, diet, and bio-
markers. Over half a million people were recruited in 10
European countries. In Heidelberg and surrounding areas,
25,546 participants aged 35–64 were enrolled at random
from 1994 to 1998. Biological specimens were collected
from 24,235 participants [29]. Regular follow-ups are
conducted every 2–3 years with the aim to gain informa-
tion on incident diseases, in particular cancer, including
prelesions such as CRA. Other baseline characteristics,
recruitment procedures, of the population-based study are
reported elsewhere [30]. All participants signed a consent
form at baseline, and the ethical committee of the Hei-
delberg Medical School has approved the current study.
A nested case–control study was conducted within
EPIC-Heidelberg among 5,064 participants who had stated
in the follow-up that they had had a colonoscopy. Among
those, we identified 536 adenoma cases between start of
recruitment (1994) and December 2005. CRA was verified
and coded relying on the 2nd version of the International
Classification of Diseases for Oncology (ICD-O2). Four
hundred and forty-four cases were included in the study
after exclusion of prevalent and incident cases of cancer
(except non-melanoma skin cancer), stroke, or myocardial
infarction. For each case, 2 controls matched by age at
colonoscopy (±1 year), sex, and recruitment year
(±0.5 year) were selected among those who had had a
negative colonoscopy because adenomas are known to be
quite often undetected for a long time and who were free of
cancer, stroke, and myocardial infarction. Due to missing
information on HCA intake or miscarried genotyping, our
case–control set finally consisted of 413 cases and 796
controls.
Assessment of HCA exposure
Dietary intake was assessed by a validated 158-item food
frequency questionnaire (FFQ) at baseline [31] based on
self-evaluation. Detailed information on meat consumption
and preparation during the last 12 months was collected. In
the second follow-up (2001–2003), participants addition-
ally provided information on the degree of browning, based
on pictures showing meat lightly, moderately, strongly or
extreme browned, and preferred cooking methods for meat
[32]. Due to this supplementary information, the intake of
the most abundant HCAs (PhIP, MeIQx, DiMeIQx) was
calculated for the EPIC-Heidelberg cohort, relying on
published data [33, 34].
Laboratory analyses
Genomic DNA was extracted from buffy coats with Flex-
iGene kit (Qiagen Hilden, Germany) in accordance with
the manufacturer’s instructions. Genotyping was performed
at Bioglobe (Hamburg, Germany). CYP1A2 (A-164C,
rs762551), NAT1 (C1095A, rs15561), NAT2 (T341C,
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rs1801280; G590A, rs1799930), SULT1A1 (G638A, rs928
2861), GSTA1 (G-52A, rs3957357), UGT1A7 (T [ G, rs17
868323; G [ A, rs17868324; T [ C, rs11692021), and UG
T1A9 (A(T)9/10AT, rs3832043) genotypes were deter-
mined as multiplex on the MassArray system (Sequenom,
San Diego, USA) applying the iPLEX method and matrix-
assisted laser desorption/ionization (MALDI-TOF). Inter-
experimental reproducibility and accuracy was verified by
8 % of duplicated samples presenting concordant genotype
results. Genotyping of NAT1 (T1088A, rs1057126; G560A,
rs4986782) and NAT2 (G857A, rs1799931) was performed
in Heidelberg using a LightCycler 480 (Roche, Mannheim,
Germany) hybridization technology with real-time poly-
merase chain reaction (PCR) and melting curve analysis.
Determination was carried out in triplicate and a SD
of [10 % led to repeated analysis. Quality control was
done by repeating analyses for 5 % of the samples,
resulting in accordance with [95 % of the assigned
genotypes. All laboratory analyses were carried out with
the laboratory personnel blinded to the case–control status.
Statistical analyses
In CYP1A2, the CYP1A2*1F polymorphism (rs762551)
A-164C was determined. The homozygous carriers of the
A allele were classified as having normal enzyme activity,
whereas carriers of the CA or CC alleles as having rapid
activity [35]. In NAT1, 3 SNPs were determined: T1088A
(rs1057126), G560A (rs4986782), and C1095A (rs15561)
to classify the NAT1*4 (wild type), NAT1*10 (T1088A and
C1095A), NAT1*11 (C1095A), and NAT1*14 allele
(T1088A, C1095A, and G560A). For NAT1, no phenotypes
were predicted due to controversial information on the
phenotypic enzyme activity in the literature. Therefore,
genotypes were presented, whereas *10/*10 alleles and
*10/*others alleles were pooled into one group, due to the
small number in each group. Three SNPs were evaluated in
NAT2 (wild type NAT2*4 allele) [T341C (NAT2*5,
rs1801280), G590A (NAT2*6, rs1799930), and G857A
(NAT2*7, rs1799931)] to predict two phenotypes: Rapid
acetylators were defined as carriers of at least one NAT2*4
allele (*4/*4, *4/*5, *4/*6, *4/*7) and all other combina-
tions as slow phenotypes (*5/*5, *5/*6, *5/*7, *6/*6, *6/
*7, *7/*7).
Three SNPs in UGT1A7 [T387G (rs17868323, Asp129Lys),
G392A (rs17868324, Arg131Lys), and T622C (rs11692021,
Trp208Arg)] were used to identify carriers of the UGT1A7*1
allele (wild type), the UGT1A7*2 allele (Asp129Lys and
Arg131Lys), the UGT1A7*3 allele (Asp129Lys, Arg131Lys,
and Trp208Arg) and the UGT1A7*4 allele (Trp208Arg). These
four alleles were used to determine phenotypes with slow (*3/
*3, *3/*4, *4/*4), intermediate (*1/*3, *1/*4, *2/*3, *2/*4),
and rapid enzyme activity (*1/*1, *1/*2, *2/*2) [36]. SULT1A1
(rs9282861) enzyme activity was defined as normal activity
with carriers of the GG (*1/*1) and GA (*1/*2) alleles, while
the AA (*2/*2) alleles were defined as having slow activity
[37]. For GSTA1 (rs3957357), GG or GA alleles result in nor-
mal activity and AA in slow activity [38]. For UGT1A9, indi-
viduals with deletions at rs3832043 (A(T)9AT) were classified
as having normal activity, whereas DEL/T or TT ((T)10AT)
variants are leading to rapid activity [39]. An overview of the
predicted phenotypes is given in Table 1.
Firstly, the association of HCA intake with the CRA risk
was calculated using conditional logistic regression strati-
fied by case set. PhIP, MeIQx, and DiMeIQx were stratified
into quartiles based on the distribution in controls. Con-
founders were selected due to known results from litera-
ture: history of familial colon cancer (yes/no), smoking
status (never, former, or current), pack-years of smoking,
regular use of non-steroidal anti-inflammatory drugs
(NSAID) (yes/no), waist circumference, alcohol con-
sumption, and fat intake. Inclusion of variables other than
the aforementioned confounders did not materially influ-
ence the results (e.g., physical activity, BMI, fruit intake,
fiber intake, energy intake). Secondly, we evaluated
potential effect modification of the association between the
intake of HCAs and the risk of CRA by selected poly-
morphisms. Therefore, we calculated OR (and 95 % CI) of
CRA for HCA quartiles stratified by phenotype with
unconditional logistic regression adjusting for sex and age
(i.e., matching factors) and additionally for the confounders
mentioned above (multivariable adjustment). Tests for
interaction were done using the cross-product terms of
HCA quartiles and the selected phenotypes. The effect
modification and correspondent test for interaction was
also calculated with HCAs as continuous variables.
Thirdly, we were interested in high-risk phenotype group
vs. low-risk phenotype group. Thus, we built groups of
enzymes that possibly accelerate the progress of develop-
ing CRA (high activating and slow detoxifying HCA
enzymes) and groups of enzymes, which may reduce the
development of CRA (slow activating and high detoxifying
HCA enzymes). At least 4 of the 7 enzymes had to be in the
according phenotype group. A third group included all
remaining enzyme combinations. Low-CRA-risk group
was defined when at least four of seven following pheno-
types were available: rapid CYP1A2, NAT1*10/*10 or
NAT1*10/other, rapid NAT2, intermediate SULT1A1,
slow GSTA1, slow UGT1A7, and normal UGT1A9. High-
CRA-risk group was defined when at least four of seven
following phenotypes were available: normal CYP1A2,
NAT1*4/*4, slow NAT2, slow SULT1A1, normal GSTA1,
rapid UGT1A7, and rapid UGT1A9. The remaining
enzyme combinations were assigned to the intermediate-
CRA-risk group. The effect of these enzyme groups on the
association of HCA intake with the risk of CRA was
Cancer Causes Control (2012) 23:1429–1442 1431
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calculated with unconditional logistic regression, whereas
the reference categories consisted of participants in the
lowest quartile of HCAs. Finally, a sensitivity analysis was
conducted to evaluate the effect of the late implementation
on the food questionnaire; that is, we excluded all cases
that were diagnosed before the meat preparation ques-
tionnaire was applied (n = 228). Two-sided p \ 0.05 was
considered statistically significant. All statistical analyses
were conducted using STATA version 11.
Results
Table 2 shows the baseline characteristics of the study
population. Cases were more likely to be former or current
smokers than controls and had a higher level of pack-years
of smoking than controls. Additionally, family history of
colon cancer and alcohol consumption was more common
in cases than in controls. Neither BMI nor waist circum-
ference differed significantly between cases and controls.
Education level was distributed similarly between the two
groups. No statistically significant differences were
observed for physical activity, NSAID use at baseline
and fat intake between cases and controls. Median PhIP,
MeIQx, and DiMeIQx intake were higher in cases than in
controls.
There was an elevated risk of CRA with increasing
PhIP, MeIQx, and DiMeIQx intake, which remained sta-
tistically significant after adjusting for confounders
(p trend = 0.006, 0.022, 0.045, respectively; Table 3). A
sensitivity analysis including only cases diagnosed after
applying the 2nd FFQ did not reveal results materially
different from results of the complete case group.
SNPs in 7 genes of phase I or phase II carcinogen-
metabolizing enzymes were analyzed. As reported earlier
[27], main effects of genotypes on CRA risk were restricted
to SNPs in NAT1 (rs15561 and rs1057126; rarer alleles
were inversely associated with CRA risk, but no statisti-
cally significant effects were observed for predicted
phenotypes), NAT2 (combined genotype: predicted med-
ium (vs. slow) acetylator phenotype with a decreased risk
of CRA), and GSTA1 (rs3957357; predicted decreased
Table 1 Overview of genotypes and predicted phenotypes
Enzyme Function of the enzyme Polymorphism site Phenotype (enzyme activity)
CYP1A2 Phase I enzyme Wild type Normal activity (*1A/*1A)
CYP1A2*1F A-164C (rs 762551) Rapid activity(*1A/*1F, *1F/*1F)
NAT1*4 Phase II enzyme Wild type No phenotypes predicted, but building of 3 groups:
NAT1*10 T1088A (rs1057126),
C1095A (rs947894)
Group 1: (*4/*4)
NAT1*11 C1095A (rs15561) Group 2: (*10/*10, *10/*other)
NAT1*14 T1088A (rs1057126),
C1095A (rs947894),
G560A (rs4986782)
Group 3: (*other/*other)
NAT2*4 Phase II enzyme Wild type Normal metabolizer (*4/*4, *4/*5, *4/*6, *4/*7)
NAT2*5 T341C (rs1801280) Slow metabolizer (*5/*5, *5/*6, *5/*7, *6/*6, *6/
*7, *7/*7)
NAT2*6 G590A (rs1799930)
NAT2*7 G857A (rs1799931)
SULT1A1*1 Phase II enzyme Wild type Normal activity (*1/*1, *1/*2)
SULT1A1*2 G638A (rs9282861) Slow activity (*2/*2)
GSTA1*A Phase II enzyme Wild type Normal activity (*A/*A, A/*B)
GSTA1*B C-69T (rs 3957357) Slow activity (*B/*B)
UGT1A7*1 Phase II enzyme Wild type Rapid activity (*1/*1, *1/*2, *2/*2)
UGT1A7*2 asp129lys (T387G, rs17868323),
arg131lys (G392A, rs17868324)
Intermediate activity (*1/*3, *1/*4, *2/*3, *2/*4)
UGT1A7*3 asp129lys (T387G, rs17868323),
arg131lys (G392A, rs17868324),
trp208arg (T622C, rs11692021)
Slow activity (*3/*3, *3/*4, *4/*4)
UGT1A7*4 trp208arg (T622C, rs11692021)
UGT1A9*1 Phase II enzyme Wild type, A(T)9AT Normal activity (*1/*1)
UGT1A9*22 A(T)10AT (rs3832043) Rapid activity (*22/*22, *1/*22)
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enzyme activity (AA carriers) associated with a lower CRA
risk).
The results of the analysis on interactive effects between
genotypes and HCA intake on CRA risk are given in
Table 4; we present multivariable adjusted results because
age- and sex-adjusted results did not differ materially but
were less conservative.
Statistically significant effect modification was found in
one gene. SULT1A1 predicted phenotypes modified the
effect of MeIQx on CRA risk (pInteraction [ 0.01). The
association of MeIQx intake with CRA risk was stronger
for slow than for normal predicted phenotypes (4th vs. 1st
quartiles OR 3.61, 95 % CI 0.92–14.24, OR 1.22, 95 % CI
0.82–1.80, respectively). Using MeIQx as a continuous
Table 2 Baseline characteristics of cases and controls in the case–control study nested in the European Prospective Investigation into Cancer
and Nutrition (EPIC)-Heidelberg study
Cases (n = 413) Controls (n = 796) pa
n (%)b n (%)b
Colorectal adenoma characteristics
Adenoma location
Right colon 114 (27.6)
Left colon 149 (36.1)
Rectum 93 (22.5)
Missing 57 (13.8)
General characteristics
Age at baseline, mean ± SD 54.5 (±6.20) 54.6 (±6.24)
Males 270 (34.2) 520 (65.8)
Females 143 (34.1) 276 (65.9)
BMI males, mean ± SD 26.91 (±2.91) 26.74 (±3.18) 0.47
BMI females, mean ± SD 25.30 (±3.99) 25.55 (±3.89) 0.57
Waist circumference males (cm), mean ± SD 96.51 (±8.94) 96.28 (±8.89) 0.74
Waist circumference females (cm), mean ± SD 81.96 (±10.71) 81.74 (±11.66) 0.85
Education
None or primary school 126 (30.5) 249 (31.3)
Technical or professional school 138 (33.4) 252 (31.7)
Secondary school 24 (5.8) 41 (5.2)
University degree 125 (30.3) 254 (31.9) 0.85
Smoking status
Never 140 (33.9) 316 (39.7)
Former 191 (46.3) 364 (45.7)
Current 82 (19.9) 116 (14.6) 0.02
Pack-years of smoking, mean ± SD 11.86 (±17.11) 9.53 (±15.71) 0.02
Physical activity
Inactive 48 (11.8) 84 (10.7)
Moderately inactive 149 (36.6) 300 (38.1)
Moderately active 121 (29.7) 216 (27.5)
Active 89 (21.9) 187 (23.8) 0.77
NSAID (use at baseline) 39 (9.4) 94 (11.8) 0.23
Alcohol intake (g/d), mean ± SD 24.5 (±27.6) 20.3 (±23.7) 0.01
Fat intake (g/d), mean ± SD 77.0 (±30.9) 74.7 (±29.1) 0.21
Family history of colon cancer 71 (17.2) 89 (11.2) 0.01
Intake of heterocyclic aromatic amines (ng/d)
PhIP, median (interquartile range) 22.64 (9.83–58.72) 17.63 (6.77–42.34) 0.001
MeIQx, median (interquartile range) 10.91 (4.56–25.39) 9.16 (3.77–18.98) 0.01
DiMeIQx, median (interquartile range) 1.92 (0.63–4.31) 1.69 (0.58–3.70) 0.08
a p value assessed by paired t test for continuous variables and v2 test for categorical variables
b n (number) and % if not mentioned differently
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exposure variable, we observed a statistically significant
effect modification (pInteraction [ 0.03) with an increased
risk of CRA (OR 7.94, 95 % CI 2.20–28.68) per 50 ng
increase in MeIQx for the slow SULT1A1 enzyme
activities.
For other genes, no significant effect modification was
found, but nevertheless we observed significant associa-
tions between HCA intake and CRA risk for some
phenotypes.
The CYP1A2 normal phenotype and the rapid
CYP1A2*1F (predicted) phenotype did not modify the
increasing risk of CRA for higher intake of PhIP, MeIQx,
and DiMeIQx (pInteraction [ 0.05). However, the associa-
tion of PhIP intake with CRA was significant only in the
rapid phenotype for the 4th quartile compared with the 1st
quartile (OR 1.77; 95 % CI 1.05–2.98). For NAT1 geno-
types, there was a significantly increased risk of CRA in the
*4/*4 alleles group (wild type) for the 4th quartile of PhIP
compared with the 1st quartile (OR 1.91; 95 % CI
1.14–3.21), but the interaction between (predicted) phe-
notype and HCA intake on CRA risk was not statistically
significant (pInteraction [ 0.05). For NAT2 slow metaboliz-
ing phenotype, we observed a significantly increased CRA
risk for high vs. low intake of PhIP (OR 1.80, 95 % CI
1.14–3.21). Intake of PhIP with CRA risk for the SULT1A1
normal phenotype (OR 1.61, 95 % CI 1.08–2.40) showed a
statistically significantly positive association. An increased
risk of CRA was observed with increasing PhIP intake for
the GSTA1 normal predicted phenotype in the 4th quartile
compared to the 1st quartile (OR 1.82, 95 % CI 1.20–2.77).
In contrast, the association of MeIQx and DiMeIQx with
the risk of CRA did not increase significantly for the
GSTA1 phenotype. UGT1A7 phenotypes had no modifying
effect on the association of HCA with CRA. However, the
increase in CRA risk with increasing HCA intake was
strongest among participants with slow phenotype (OR
3.02, 95 % CI 1.02–8.94, 1st vs. 4th quartile). For the rapid
phenotype of UGT1A9, there was a statistically significant
increased risk of CRA with an OR of 1.97 (95 % CI
1.23–3.16) in the 4th quartile of PhIP compared to the 1st
quartile, but there was no significant association for the
normal activity phenotype. All analyses were repeated
using HCA intake as continuous variable.
Figure 1 shows the associations of HCA intake with
CRA risk for three phenotype groups derived from genetic
variants in HCA-metabolizing enzymes. Increasing HCA
intake was positively associated with CRA for the low-risk
groups. For PhIP, this result was statistically significant
Table 3 Odds ratio (95 % CI) for colorectal adenomas by quartiles of heterocyclic aromatic amine intakea, in the case–control study nested in
EPIC-Heidelberg
No. of cases No. of controls OR (95 % CI)b
Unadjusted
OR (95 % CI)b
Multiple adjustedc
PhIP (ng/d)
0–6.72 78 199 1 1
[6.72–17.62 89 199 1.15 (0.79–1.66) 1.24 (0.87–1.78)
[17.62–42.31 112 199 1.47 (1.03–2.09) 1.26 (0.88–1.81)
[42.31 134 199 1.75 (1.23–2.49) 1.81 (1.24–2.64)
p trend 0.002 0.006
MeIQx (ng/d)
0–3.77 86 199 1 1
[3.77–9.15 94 199 1.11 (0.78–1.59) 1.11 (0.77–1.61)
[9.15–18.96 103 199 1.23 (0.86–1.75) 1.20 (0.83–1.73)
[18.96 130 199 1.57 (1.10–2.24) 1.45 (0.99–2.12)
p trend 0.008 0.022
DiMeIQx (ng/d)
0–0.58 91 199 1 1
[0.58–1.69 101 199 1.11 (0.79–1.56) 1.11 (0.78–1.57)
[1.69–3.70 93 199 1.02 (0.72–1.45) 0.96 (0.67–1.37)
[3.70 128 199 1.46 (1.01–2.06) 1.35 (0.94–1.93)
p trend 0.027 0.045
a PhIP:2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine; MeIQx: 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline; DiMeIQx: 2-amino-3,4,8-
dimethylimidazo[4,5-f]quinoxaline
b Conditional logistic regression stratified by case set
c Adjusted for NSAIDs, family history of colorectal cancer, smoking (never, former, current), pack-years of smoking, waist circumference,
alcohol intake, fat intake
1434 Cancer Causes Control (2012) 23:1429–1442
123
Table 4 OR (95 % CI) for the association between the intake of PhIP, MeIQx, and DiMeIQx stratified in quartiles with the risk of CRA in strata
of genetic polymorphisms in the EPIC-Heidelberg nested case–control study (n = 1,209)
Phenotypea
CYP1A2 Normal Rapid pb
Cases/
Controls
OR (95 % CI) Cases/
Controls
OR (95 % CI)
PhIP
0–6.72 38/86 1 40/110 1
[6.72–17.62 45/97 0.98 (0.57–1.68) 43/100 1.18 (0.70–1.99)
[17.62–42.31 53/105 1.06 (0.62–1.82) 58/94 1.58 (0.94–2.64)
[42.31 62/100 1.51 (0.87–1.68) 70/97 1.77 (1.05–2.98) 0.36
per 50 ng/d intake 198/388 0.99 (0.87–1.12) 211/401 1.07 (0.95–1.20) 0.19
MeIQx
0–3.77 46/97 1 40/99 1
[3.77–9.15 40/101 0.80 (0.48–1.35) 53/97 1.35 (0.81–2.26)
[9.15–18.96 55/107 1.13 (0.69–1.87) 48/92 1.18 (0.70–2.01)
[18.96 57/83 1.46 (0.85–2.50) 70/113 1.27 (0.75–2.13) 0.75
per 50 ng/d intake 198/388 1.28 (0.91–1.80) 211/401 1.34 (0.91–1.97) 0.36
DiMeIQx
0–0.58 45/99 1 46/98 1
[0.58–1.69 42/98 0.90 (0.53–1.51) 57/98 1.15 (0.70–1.88)
[1.69–3.70 54/95 1.15 (0.69–1.90) 38/103 0.70 (0.41–1.18)
[3.70 57/96 1.24 (0.74–2.08) 70/102 1.22 (0.75–2.00) 0.83
per 10 ng/d intake 198/388 1.28 (0.91–1.80) 211/401 1.50 (1.01–2.21) 0.28
NAT1 *4/*4 *10/*other und *10/*10 Other
Cases/Controls OR (95 % CI) Cases/Controls OR (95 % CI) Cases/Controls
PhIP
0–6.72 44/95 1 19/61 1 9/28 1
[6.72–17.62 41/111 0.80 (0.47–1.35) 30/60 1.71 (0.83–3.54) 10/22 1.42 (0.61–6.51)
[17.62–42.31 66/99 1.39 (0.84–2.30) 28/65 1.46 (0.69–3.10) 10/18 1.99 (0.61–6.51)
[42.31 80/94 1.91 (1.14–3.21) 36/65 1.98 (0.93–4.20) 10/28 0.82 (0.23–2.92) 0.62
per 50 ng intake 231/399 1.04 (0.93–1.15) 113/251 1.11 (0.92–1.35) 39/96 0.94 (0.57–1.53) 0.37
MeIQx
0–3.77 50/94 1 20/68 1 8/26 1
[3.77–9.15 50/103 0.86 (0.52–1.41) 24/57 1.41 (0.68–2.93) 14/30 1.59 (0.50–5.00)
[9.15–18.96 56/113 0.90 (0.55–1.47) 32/61 1.73 (0.84–3.55) 8/12 2.80 (0.71–11.08)
[18.96 75/89 1.46 (0.88–2.42) 37/65 1.99 (0.95–4.17) 9/28 0.84 (0.20–3.46) 0.3
per 50 ng/d intake 231/399 1.38 (0.96–1.97) 113/251 1.67 (0.92–3.02) 39/96 1.23 (0.74–2.04) 0.38
DiMeIQx
0–0.58 55/106 1 22/59 1 9/22 1
[0.58–1.69 50/94 0.98 (0.60–1.59) 31/64 1.03 (0.51–2.09) 10/23 1.22 (0.37–4.01)
[1.69–3.70 55/110 0.88 (0.55–1.42) 22/51 1.12 (0.53–2.34) 9/30 0.63 (0.19–2.13)
[3.70 71/89 1.47 (0.91–2.39) 38/77 1.02 (0.50–2.08) 11/21 1.16 (0.32–4.15) 0.63
per 10 ng/d intake 231/399 1.37 (0.98–1.03) 113/251 1.46 (0.79–2.71) 39/96 1.26 (0.56–2.83) 0.78
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Table 4 continued
NAT2 Normal Slow
Cases/Controls OR (95 % CI) Cases/Controls OR (95 % CI)
PhIP
0–6.72 30/89 1 47/98 1
[6.72–17.62 42/86 1.43 (0.80–2.55) 43/106 0.85 (0.51–1.42)
[17.62–42.31 34/86 1.11 (0.60–2.04) 73/107 1.38 (0.85–2.24)
[42.31 52/90 1.68 (0.93–3.05) 76/97 1.80 (1.09–2.99) 0.8
per 50 ng/d intake 158/351 1.02 (0.88–1.87) 239/408 1.05 (0.95–1.17) 0.81
MeIQx
0–3.77 31/87 1 52/102 1
[3.77–9.15 40/91 1.39 (0.78–2.47) 52/103 0.89 (0.55–1.46)
[9.15–18.96 34/89 1.15 (0.63–2.09) 65/103 1.18 (0.73–1.89)
[18.96 53/84 1.87 (1.02–3.43) 70/100 1.27 (0.78–2.08) 0.32
per 50 ng/d intake 158/351 1.54 (1.00–2.37) 239/408 1.27 (0.91–1.77) 0.5
DiMeIQx
0–0.58 30/84 1 58/109 1
[0.58–1.69 42/83 1.42 (0.79–2.53) 55/100 0.99 (0.62–1.59)
[1.69–3.70 33/88 0.97 (0.53–1.75) 58/104 0.94 (0.58–1.50)
[3.70 53/96 1.51 (0.85–2.69) 68/95 1.29 (0.80–2.06) 0.63
per 10 ng/d intake 158/351 0.13 (0.00–7.23) 239/408 1.72 (1.12–2.64) 0.49
SULT1A1 Normal Slow
Cases/Controls OR (95 % CI) Cases/Controls OR (95 % CI)
PhIP
0–6.72 67/175 1 11/19 1
[6.72–17.62 84/179 1.23 (0.83–1.81) 4/18 0.35 (0.08–1.53)
[17.62–42.31 100/180 1.37 (0.93–2.02) 11/19 0.98 (0.29–3.32)
[42.31 113/178 1.61 (1.08–2.40) 19/19 2.07 (0.63–6.80) 0.28
per 50 ng intake 364/712 1.01 (0.93–1.11) 45/75 1.36 (0.92–2.02) 0.12
MeIQx
0–3.77 76/178 1 10/16 1
[3.77–9.15 88/174 1.18 (0.81–1.72) 5/24 0.25 (0.06–1.10)
[9.15–18.96 94/177 1.21 (0.83–1.77) 9/22 0.70 (0.20–2.43)
[18.96 106/183 1.22 (0.82–1.80) 21/13 3.61 (0.92–14.24) 0.01
per 50 ng/d intake 364/712 1.19 (0.93–1.53) 45/75 7.94 (2.20–28.68) 0.03
DiMeIQx
0–0.58 83/181 1 8/16 1
[0.58–1.69 87/175 1.07 (0.74–1.55) 12/19 0.89 (0.25–3.14)
[1.69–3.70 84/170 1.01 (0.69–1.47) 8/28 0.50 (0.13–1.82)
[3.70 110/186 1.17 (0.80–1.69) 17/12 2.94 (0.80–10.77) 0.08
per 10 ng/d intake 364/712 1.26 (0.96–1.65 45/75 4.07 (1.25–13.26) 0.07
GSTA1 Normal Slow
Cases/Controls OR (95 % CI) Cases/Controls OR (95 % CI)
PhIP
0–6.72 66/163 1 12/36 1
[6.72–17.62 78/150 1.29 (0.86–1.94) 11/47 0.73 (0.28–1.93)
[17.62–42.31 94/165 1.33 (0.89–1.98) 18/34 1.69 (0.66–4.34)
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Table 4 continued
GSTA1 Normal Slow
Cases/
Controls
OR (95 % CI) Cases/
Controls
OR (95 % CI)
[42.31 111/145 1.82 (1.20–2.77) 23/54 1.51 (0.61–3.77) 0.43
per 50 ng/d
intake
349/623 1.04 (0.95–1.15) 64/171 1.03 (0.86–1.25) 0.6
MeIQx
0–3.77 72/154 1 14/44 1
[3.77–9.15 78/156 1.07 (0.72–1.60) 16/43 1.18 (0.50–2.79)
[9.15–18.96 91/158 1.23 (0.82–1.82) 12/41 0.72 (0.28–1.86)
[18.96 108/155 1.34 (0.89–1.82) 22/43 1.46 (0.62–3.47) 0.91
per 50 ng/d
intake
349/623 1.44 (1.05–1.97) 64/171 0.99 (0.55–1.80) 0.14
DiMeIQx
0–0.58 76/149 1 15/49 1
[0.58–1.69 87/165 1.00 (0.68–1.47) 14/33 1.42 (0.58–3.46)
[1.69–3.70 81/152 0.98 (0.66–1.45) 12/47 0.66 (0.26–1.63)
[3.70 105/157 1.15 (0.78–1.71) 23/42 1.75 (0.75–4.08) 0.62
per 10 ng/d
intake
349/623 1.62 (1.17–2.24) 64/171 1.02 (0.62–1.67) 0.08
UGT1A7 Intermediate Rapid Slow
Cases/Controls OR (95 % CI) Cases/Controls OR (95 % CI) Cases/Controls OR (95 % CI)
PhIP
0–6.72 38/84 1 31/80 1 9/33 1
[6.72–17.62 35/95 0.79 (0.45–1.37) 35/76 1.29 (0.70–2.37) 18/25 2.77 (0.99–7.77)
[17.62–42.31 63/102 1.23 (0.73–2.06) 32/67 1.24 (0.66–2.34) 16/30 2.20 (0.77–6.34)
[42.31 65/95 1.37 (0.80–2.33) 49/80 1.71 (0.91–3.20) 19/22 3.02 (1.02–8.94) 0.94
per 50 ng/d intake 201/376 0.98 (0.86–1.13) 147/303 1.03 (0.90–1.17) 62/110 1.16 (0.92–1.47) 0.57
MeIQx
0–3.77 41/89 1 33/72 1 12/34 1
[3.77–9.15 43/93 0.97 (0.57–1.65) 35/78 1.06 (0.58–1.94) 15/28 1.59 (0.60–4.24)
[9.15–18.96 53/102 1.06 (0.63–1.76) 35/74 1.05 (0.57–1.92) 15/23 2.04 (0.74–5.86)
[18.96 64/92 1.27 (0.76–2.17) 44/79 1.23 (0.66–2.29) 20/25 2.09 (0.75–5.85) 0.93
per 50 ng/d intake 201/376 1.18 (0.87–1.60) 147/303 1.46 (0.91–2.34) 62/110 1.24 (0.54–2.86) 0.79
DiMeIQx
0–0.58 46/86 1 26/72 1 19/38 1
[0.58–1.69 41/94 0.75 (0.45–1.27) 46/76 1.64 (0.89–3.00) 13/26 1.07 (0.42–2.71)
[1.69–3.70 47/101 0.81 (0.49–1.35) 36/79 1.15 (0.61–2.15) 10/19 1.09 (0.40–2.97)
[3.70 67/95 1.15 (0.70–1.91) 39/76 1.36 (0.72–2.56) 20/27 1.31 (0.52–3.33) 0.56
per 10 ng/d intake 201/376 1.25 (0.89–1.74) 147/303 1.41 (0.86– 2.29) 62/110 1.53 (0.68–3.40) 0.73
UGT1A9 Normal Rapid
Cases/Controls OR (95 % CI) Cases/Controls OR (95 % CI)
PhIP
0–6.72 31/72 1 47/127 1
[6.72–17.62 37/76 1.05 (0.57–1.91) 51/121 1.24 (0.77–2.01)
[17.62–42.31 44/73 1.37 (0.74–2.53) 68/126 1.43 (0.90–2.29)
[42.31 40/73 1.28 (0.67–2.53) 93/125 1.97 (1.23–3.16) 0.12
per 50 ng/d intake 152/294 1.01 (0.87–1.18) 259/495 1.05 (0.94–1.16) 0.52
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(4th vs. 1st quartile, OR 2.25, 95 % CI 1.33–3.83).
Between phenotype risk groups and HCA intake, no sig-
nificant interaction (pInteraction [ 0.05) was observed.
Discussion
In the current study, we observed a statistically significant
increased risk of CRA with increasing HCA intake (PhIP,
MeIQx, and DiMeIQx), as shown previously in a cohort
design [21]. In general, HCA intake and CRA risk were
positively associated when stratified by phenotypes of
single enzymes. There was no effect modification on the
association between HCA intake and CRA risk by genetic
polymorphisms, with the exception of SULT1A1 and
MeIQx intake. Comparing groups of enzymes, we did not
find any significant effect modification. However, in the
4th quartile of slow HCA-activating phenotypes or of rapid
HCA-detoxifying phenotypes, significant results were
obtained for PhIP.
CYP1A2 phase 1 enzymes are involved in the first step
of metabolism of HCA. The CYP1A2*F polymorphism is
associated with enhanced enzyme activity [26]. Neverthe-
less, in our study, there was no modifying effect of
CYP1A2 on the association of HCA with CRA risk, which
is in accordance with other studies looking at meat and
HCA intake on the CRC or CRA risk [13, 19].
There are still uncertainties about definition of pheno-
types predicted from genotypes of NAT1, due to the lack of
comprehension of NAT1 effects [40]. This might be a
reason for inconsistent results. The study of Ishibe et al.
[13] with 146 cases observed an increased CRA risk for
NAT1 rapid acetylators with high MeIQx consumption. The
rapid acetylators were defined as having at least one
NAT1*10 allele. In contrast, the study of Shin et al. [19]
with 557 CRA cases considered NAT1*10 and NAT1*11
alleles as rapid acetylators only in combination or hetero-
zygous with a NAT1*3 and NAT1*4 allele. They observed
an association of high HCA intake with risk for polyps
among participants with high activity NAT1 or NAT2
genotypes. Similar results were obtained from the above-
mentioned Hawaiian study [41]. The study of Tiemersma
et al. [14] looked at total meat intake and found a higher
CRA risk for slow NAT2 acetylators than for intermediate/
fast phenotypes. In our study, there was no effect modifi-
cation by NAT1 or NAT2. Concerning main effects, we had
previously reported that carriers of the combined NAT2
alleles encoding for enzymes with medium (versus slow)
activity had a significantly lower adenoma risk
(OR = 0.75; 95 % CI 0.85–0.97). Compared to individuals
carrying two NAT1*4 alleles, all other predicted NAT1
phenotypes were associated with a non-significantly
decreased risk of colorectal adenomas [27].
We observed modifying effects of SULT1A1 phenotypes
on the association of MeIQx intake with CRA risk, with
slow phenotypes having the highest CRA risk. Up to our
knowledge, there is one Dutch study [14] examining the
effect of SULT1A1 polymorphisms on the association of
meat consumption with CRA risk in a case–control setting
with 431 CRA cases. It did not reveal any effect
Table 4 continued
UGT1A9 Normal Rapid
Cases/
Controls
OR (95 % CI) Cases/
Controls
OR (95 % CI)
MeIQx
0–3.77 35/70 1 51/128 1
[3.77–9.15 37/79 0.94 (0.52–1.68) 56/120 1.25 (0.78–1.99)
[9.15–18.96 37/77 1.04 (0.57–1.88) 66/122 1.32 (0.83–2.09)
[18.96 43/68 1.27 (0.67–2.41) 86/129 1.55 (0.98–2.46) 0.47
per 50 ng/d
intake
152/294 1.05 (0.95–1.16) 259/495 1.06 (0.99–1.03) 0.55
DiMeIQx
0–0.58 41/80 1 50/117 1
[0.58–1.69 34/69 1.06 (0.59–1.88) 66/129 1.10 (0.70–1.74)
[1.69–3.70 32/62 1.07 (0.59–1.93) 61/137 0.94 (0.59–1.49)
[3.70 45/83 1.07 (0.60–1.90) 82/116 1.50 (0.94–2.37) 0.16
per 10 ng/d
intake
152/294 1.52 (0.95–2.44) 259/495 1.34 (0.98–1.83) 0.99
a All results are multivariable adjusted
b p value for test for interaction between HCA intake and phenotype
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modification of SULT1A1, although intermediate/fast phe-
notypes had a higher CRA risk than slow phenotypes.
Concerning CRC, a Canadian case–control study [42]
found a modifying effect of SULT1A1 combined with
CYP1B1 on the association between red meat doneness
intake and CRC risk. The SULT1A1 GG genotype that
corresponds to our intermediate phenotype had higher CRC
risk than the GA/AA genotypes. A German case–control
study [43] reported that low-activity SULT1A1*2 alleles
were associated with higher CRC risk. Since SULTs are
involved in both activation and detoxification of HCAs
[44], this may explain the inconsistent results. Due to
multiple comparisons and the small number of our slow
SULT1A1 phenotypes, it warrants further study on the
effects of SULT enzymes on HCA intake and CRA risk.
According to the metabolizing process of HCAs,
enzymes of the GST and UGT family detoxify carcino-
genic HCAs. Thus, slow detoxifying polymorphisms of this
group may be associated with a higher CRA risk than high
detoxifying GST and UGT enzymes. However, we had
previously reported a decreased risk of colorectal adeno-
mas among those participants with the low-activity GSTA1
phenotype [27], which has also been reported in a study on
gastric cancer [45]. When looking at interaction effects, we
observed a significant association of PhIP intake with CRA
risk for the GSTA1 phenotype with normal activity. How-
ever, one case–control study [46] looked at consumption of
well-done meat and CRC and found a higher OR for sub-
jects with the combination of high intake of well-done meat
and the low-activity GSTA1 phenotype.
One case–control study examined the effect of UGT1A7
[36] and observed an increased CRC risk for PhIP and
DiMeIQx regardless of phenotypes (slow vs. high/inter-
mediate phenotypes). We observed no effect modification
by UGT1A7 phenotype, but observed a stronger association
between PhIP intake and CRA risk among those with slow
phenotype. Concerning UGT1A9, we also observed no
statistically significant effect modification, although there
was once again a stronger association between PhIP intake
and CRA risk among those with slow phenotype. To the
best of our knowledge, no other studies concerning this
gene have been published in this regard.
To the best of our knowledge, there is no study com-
paring a score of high-CRA-risk phenotypes vs. low-CRA-
risk phenotypes constructed on the basis of the genotype
information. Although the test for interaction does not
indicate an overall effect modification, we got indication of
a dose–response relationship in subjects with a ‘‘low CRA
risk’’ phenotype (significant effect for the highest versus
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Fig. 1 Multivariate adjusted OR of CRA according to quartiles of
PhIP (a), MeIQx (b), and DiMeIQx (c) intake and three phenotype
groups derived from genetic variants in HCA-metabolizing enzymes.
Low-CRA-risk group is defined when at least four of seven following
phenotypes were available: rapid CYP1A2, NAT1*10/*10, or
NAT1*10/other, rapid NAT2, intermediate SULT1A1, slow GSTA1,
slow UGT1A7, intermediate UGT1A9. High-CRA-risk group is
defined when at least four of seven following phenotypes were
available: intermediate CYP1A2, NAT1*4/*4, slow NAT2, slow
SULT1A1, intermediate GSTA1, rapid UGT1A7, rapid UGT1A9.
The remaining enzyme combinations were assigned to the interme-
diate-CRA-risk group. The reference categories consist of partici-
pants in the lowest quartile of HCAs. T-bars indicate 95 %
confidence intervals for the ORs of CRA risk. pInteraction was [0.05
between phenotype risk groups and HCA intake. Cases/controls were
distributed as follows for PhIP (1st to 4th HCA quartiles): 11/36,
17/26, 19/38, 30/27 (low-CRA-risk group); 65/157, 63/164, 89/154,
101/161 (intermediate-CRA-risk group); 2/6, 9/9, 4/7, 3/11 (high-
CRA-risk group). For MeIQx (1st to 4th HCA quartiles): 15/34,
14/26, 23/34, 25, 33 (low-CRA-risk group); 66/156, 74/165, 76/162,
102/153 (intermediate-CRA-risk group); 5/9, 6/8, 4/3, 3/13 (high-
CRA-risk group). For DiMeIQx (1st to 4th HCA quartiles): 14/34,
23/34, 19/34, 21/25 (low-CRA-risk group); 70/156, 74/160, 71/161,
103/159 (intermediate-CRA-risk group); 7/9, 4/5, 3/4, 4/15 (high-
CRA-risk group)
c
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lowest intake of PhIP). Since some enzymes are involved
in both activation and detoxification of HCAs, there may
be a misclassification of these enzymes in high-, interme-
diate-, or low-risk phenotype groups. Moreover, there were
no participants in our study who had the maximum number
of exact phenotype combination to be assigned in the high-
or low-risk group. Therefore, we had to specify how much
of the predicted phenotypes had to be in each group to be
counted as high- or low-risk phenotype group, which
implicates some inaccuracy. The lack of findings does,
thus, not suggest that SNPs have no influence on the
association of HCA with CRA but might be due to a less-
sensitive definition of high- and low-risk groups.
A major strength of the study is its prospective design.
Given that this was a nested case–control study, the
selection bias was minimal. Further strengths of the study
included the well-characterized study population with
comparable cases and controls. All cases had medically
confirmed diagnoses of adenomas and controls were free of
adenomas (at least confirmed once by colonoscopy). The
detailed assessments of HCA intake and the allelic char-
acterization of chosen genes involved in the HCA metab-
olism are additional advantages of our study. Furthermore,
we were able to adjust for known confounders in our
analyses, but residual confounding cannot be completely
excluded.
Limitations of this study are the possible misclassifi-
cation of HCA intake when using a photograph-based
questionnaire. This choice of using questionnaire is nev-
ertheless justified, because the more accurate estimation of
HCA in biomaterials, for example, in hair [47], is very
expensive. Hence, this method is not available for large
epidemiological studies up to date. The potential lack of
power in our study, in particular with respect to the CRA-
risk groups, is a limitation that should be overcome with
larger studies. Additional limitation is the inclusion of
controls with negative colonoscopy, which might have
biased the results. These participants had the colonoscopy
before study inclusion and so, being in need for a colon-
oscopy, they might be less healthy and/or more health
conscious.
Further limitation is the potential for false-positive
results based on multiple comparisons. Therefore, the sig-
nificant effect modification of SULT1A1 may be due to
chance. Finally, HCA intake has been assessed in the
second follow-up, and some cases had been diagnosed
before this date. Excluding these cases from our analysis
did not materially change the observed associations.
HCA enzyme activity can be influenced not only by
genes but also by environmental factors, such as alcohol
consumption, smoking, and diet [48–50]. In addition to
HCAs, other genotoxic agents such as nitrosamines and
polycyclic aromatic hydrocarbons, which develop during
meat cooking or meat processing, may increase the CRA
and CRC risk [14, 16, 41, 50]. Up to date it remains rather
unclear in which relationship different genotoxic agents
interact to increase the CRA risk. In addition, we may have
missed some other possible phenotypes that modify the
association between HCA and CRA (e.g., GSTM1). Gene–
gene interactions may also play a role in the genesis of
CRA depending on HCA intake.
In summary, in this study, HCA intake and CRA risk
were positively associated, independent of polymorphisms
in genes involved. Because of the complex associations of
environmental factors, genotoxic agents and genetic vari-
ants, modifying effects of genotypes and their functional
correlates (enzyme activities, here called phenotypes)
might be underestimated. They are not sufficiently illumi-
nated up to date and need further research.
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